| 2020 |
Alarkawi D, Ali MS, Bliuc D, Pallares N, Tebe C, Elhussein L, Caskey FJ, Arden NK, Ben‐Shlomo Y, Abrahamsen B, Diez‐Perez A, Pascual J, Pérez‐Sáez MJ, Center JR, Judge A, Cooper C, Javaid MK, Prieto‐Alhambra D. Oral bisphosphonate use and all‐cause mortality in patients with moderate–severe (grade 3B‐5D) chronic kidney disease: a population‐based cohort study. J Bone Miner Res. May 2020;35(5):894-900. |
1 |
1 |
| 2021 |
Robinson DE, Ali MS, Pallares N, Tebé C, Elhussein L, Abrahamsen B, Arden NK, Ben-Shlomo Y, Caskey FJ, Cooper C, Dedman D, Delmestri A, Judge A, Pérez-Sáez MJ, Pascual J, Nogues X, Diez-Perez A, Strauss VY, Javaid MK, Prieto-Alhambra D. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. May 2021;36(5):820-832. |
3 |
2 |
| 2020 |
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR alliance. Osteoporos Int. April 2020;31(4):721-755. |
1 |
0 |
| 2020 |
Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Correction to: impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. April 2020;31(4):799-799. |
0 |
0 |
| 2020 |
Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Guthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR alliance. Osteoporos Int. December 2020;31(12):2425-2438. |
0 |
0 |